NCT03486327View on ClinicalTrials.gov

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

November 13, 2020

Study Completion Date

July 31, 2021

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

BR55

A novel targeted ultrasound contrast agent

Trial Locations (1)

94304

Stanford University Medical Center, Palo Alto

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Bracco Diagnostics, Inc

INDUSTRY